• Australian Clinical Labs Limited


  • Healius Limited


On 20 March 2023, Australian Clinical Labs Limited (ACL) announced that it was seeking to acquire Healius Limited (Healius) by way of an off-market takeover offer to acquire all the fully paid ordinary shares in Healius.

ACL and Healius provide human pathology services to out-patients, in-patients (at public and private hospitals), and commercial and government customers, as well as veterinary pathology services. Healius also provides diagnostic imaging services.

A Public Competition Assessment will be published in due course.


Date Event

ACCC commenced review under the Merger Process Guidelines.

Closing date for submissions.

Timeline suspended. Former provisional date for announcement of ACCC’s findings (22 June) delayed at ACL’s request. ACCC will announce a revised provisional decision date in due course. 

ACCC received further information from ACL. Timeline recommenced. 

ACCC published a Statement of Issues outlining preliminary competition concerns.

Closing date for submissions relating to Statement of Issues.

Timeline suspended pending receipt of further information.  Former proposed decision date for announcement of ACCC's findings (12 October 2023) is delayed.

ACCC commenced market consultation on proposed s87B undertaking. 

Closing date for submissions relating to the proposed s87B undertaking.

ACCC received further information. Timeline recommenced.

ACCC announced it would oppose the proposed acquisition.